Disease Progression Study for the Treatment of RRMS

Study Title
Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS
Teva Identifier
9013
ClinicalTrials.gov Identifier
NCT00202995
Study Status
Terminated
Trial Condition(s)
Relapsing Remitting Multiple Sclerosis
Interventions
Drug: Glatiramer Acetate | Drug: Betaseron | Drug: Rebif

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Print

Click for participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age Range
18 Years to 50 Years
Trial Duration
07/01/2004 - 10/01/2007
Phase
Phase 4

Study Type

Interventional